The invention provides methods for enhancing histone acylation, learning, memory and/or cognition in subjects with compound (I) or compositions comprising compound (I), or a pharmaceutically acceptable salt thereof.

Methods for transfusing blood to a mammalian subject. The method includes obtaining a unit of blood, rejuvenating the blood with an enhancement composition, measuring a level of 2,3-diphosphoglycerate in the blood, and delivering the blood to a subject.

Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.

Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin (EPO) comprise administering one or more oligonucleotide compounds designed to inhibit the EPO natural antisense transcript to patients.

Disclosed in certain embodiments is a method of decreasing gastric emptying comprising administering to a subject an effective amount of a sodium-channel blocker to decrease gastric emptying.

A method of forming an erodible sustained release tablet comprising the steps of:—a. mixing one or more therapeutic agents, one or more disintegrant and one or more molten wax, whilst retaining the wax in molten form; b. solidifying and granulating the mixture; c. forming a tablet by compression of the granules. The invention also relates to a sustained release tablet made according to the method.

The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.

The present invention provides compounds of formula (I):

##STR00001##

compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

In various aspects and embodiments, the invention provides methods of treating pulmonary arterial hypertension by inhibiting the endothelial to mesenchymal transition. The invention provides a method of treating pulmonary arterial hypertension (PAH) in a subject, the method comprising administering to the subject an agent that modulates the activity or level of let-7 mlRNA in an endothelial cell in the subject, thereby treating PAH in the subject. In another aspect, the invention provide a method of treating PAH in a subject, the method comprising administering to the subject an agent that decreases the activity or level of an endothelial TGFβ signaling polypeptide or a TGFβ peptide receptor, thereby treating PAH in the subject.

In various aspects and embodiments, the invention provides methods of treating pulmonary arterial hypertension by inhibiting the endothelial to mesenchymal transition. The invention provides a method of treating pulmonary arterial hypertension (PAH) in a subject, the method comprising administering to the subject an agent that modulates the activity or level of let-7 mlRNA in an endothelial cell in the subject, thereby treating PAH in the subject. In another aspect, the invention provide a method of treating PAH in a subject, the method comprising administering to the subject an agent that decreases the activity or level of an endothelial TGFβ signaling polypeptide or a TGFβ peptide receptor, thereby treating PAH in the subject.